Abstract:Objective: Cefoperazone/sulbactam is a commonly used antibiotic combination against the extended-spectrum beta-lactamases (ESBLs)-producing bacteria. The objective of this study was to evaluate the efficacy of a new cefoperazone/sulbactam combination (3:1) for Enterobacteriaceae infection via model-informed drug development (MIDD) approaches.Methods: Sulperazon [cefoperazone/sulbactam (2:1)] was used as a control. Pharmacokinetic (PK) data was collected from a clinical phase I trial. Minimum inhibitory concentrations (MICs) were determined using two-fold broth microdilution method. The percent time that the free drug concentration exceeded the minimum inhibitory concentration (%fT(>MIC)) was used as the pharmacokinetic/pharmacodynamic indicator correlated with efficacy. Models were developed to characterize the PK profile of cefoperazone and sulbactam. Monte Carlo simulations were employed to determine the investigational regimens of cefoperazone/sulbactam (3:1) for the treatment of infections caused by Enterobacteriaceae based on the probability of target attainment (PTA) against the tested bacteria.Results: Two 2-compartment models were developed to describe the PK profiles of cefoperazone and sulbactam. Simulation results following the single-dose showed that the regimens of cefoperazone/sulbactam combinations in the ratios of 3:1 and 2:1 achieved similar PTA against the tested bacteria. Simulation results from the multiple-dose showed that the dosing regimen of cefoperazone/sulbactam (4 g, TID, 3 g:1 g) showed slightly better antibacterial effect than cefoperazone/sulbactam (6 g, BID, 4 g:2 g) against the Escherichia coli (ESBL-) and Klebsiella pneumoniae (ESBL-). For the other tested bacteria, the above regimens achieved a similar PTA.Conclusions: Cefoperazone/sulbactam (3:1) showed similar bactericidal activity to sulperazon [cefoperazone/sulbactam (2:1)] against the tested bacteria. For the ESBL-producing and cefoperazone-resistant E. coli and K. pneumoniae, Cefoperazone/sulbactam (3:1) did not exhibit advantage as anticipated. Our study indicated that further clinical trials should be carried out cautiously to avoid the potential risks of not achieving the expected target.

In vitro and in vivo synergistic antibacterial activity of cefotaxime/sulbactam

In vitro activity of different ratios from matching cefotaxime/culbactam

Efficacy of synergistic antibiotic combinations against KPC-2 carbapenemase producing Klebsiella pneumoniae strains

In vitro antibacterial activity of cefoperazone combined with tazobactam against clinical isolates producing β-lactamases

In vitro Effect of the Combination of Aztreonam and Amoxicillin/Clavulanic Acid Against Carbapenem-Resistant Gram-Negative Organisms Producing Metallo--Lactamase

Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant Acinetobacter baumannii .

In vitro antibacterial activities of different ratios from matching cefotaxime/tazobactam

Study on enzyme stability of cefotaxime/tazobactam to β-lactamases

Antibacterial Activities of Different Concentration Ratio of Cefotaxim-Sulbactam Against the Pathogenic Microorganisms

In Vitro Antibacterial Activities of Different Ratios from Matching Cefuroxime/tazobactam Against Clinical Isolates

Treatment effects of the combination of cefuroxime and tazobactam against mouse septicemia infected by β-lactamases producing strains

In Vitro Antibacterial Activity of Cefoperazone/Tazobactam and Its Impact Factors

Antibacterial activity study of several β-lactam/β-lactamase inhibitor combinations in vitro

In Vitro Synergistic Acting of Trimethopnim and Cefalexin

Sulbactam Enhances in vitro Activity of -Lactam Antibiotics Against <i>Acinetobacter baumannii</i>

Sulbactam Enhances the in Vitro Activity of Sitafloxacin Against Extensively-Drug Resistant Acinetobacter Baumannii

In vitro effect of cefoperazone-sulbactam (2:1, 1: 1) combined with minocycline on imipenem-resistant Acinetobacter baumannii clinical isolates

New Antibiotic Compound: Ceftriaxone Sodium and Sulbactam Sodium for Injection(2:1)

Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae.

Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria

Comparison of antimicrobial activity in vitro of 7 β-lactams against 280 isolates from patients with nosocomial infections